Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

New England Journal of Medicine

Volumn 346, Issue 22, 2002, Pages 1692-1698

  Herold, Kevan C ^a   Hagopian, William ^a   Auger, Julie A ^a   Poumian Ruiz, Ena ^a   Taylor, Lesley ^a   Donaldson, David ^a   Gitelman, Stephen E ^a   Harlan, David M ^a   Xu, Danlin ^a   Zivin, Robert A ^a   Bluestone, Jeffrey A ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GLYCOSYLATED HEMOGLOBIN; HOKT3 GAMMA 1 (ALANYLALANINE); MONOCLONAL ANTIBODY CD3; OKT 3; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FEVER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; INSULIN SYNTHESIS; MALE; METABOLIC REGULATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; C-PEPTIDE; CD4-CD8 RATIO; CHILD; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LYMPHOCYTE COUNT; MALE;

EID: 0037198420     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012864     Document Type: Article

References (38)

1. Type I diabetes mellitus: A chronic autoimmune disease
2. Type 1 diabetes: New perspectives on disease pathogenesis and treatment
3. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts
4. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus
5. Factors associated with remission of type 1 diabetes in children treated with cyclosporine
6. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus
7. Cyclosporine in recent onset type I diabetes mellitus: Effects on islet beta cell function
8. Effects of cyclosporine immunosuppression in insulin-dependent diabetes meUitus of recent onset
9. Cyclosporine nephrotoxicity in type 1 diabetic patients: A 7-year follow-up study
10. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody
11. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
12. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice
13. In vivo cell activation following OKT3 administration: Systemic cytokine release and modulation by corticosteroids
14. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): Initial clinical experience
15. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection
16. Characterization of seven C-peptide antisera
17. A novel high-throughput method for accurate, rapid, and economical measurement of multiple type 1 diabetes autoantibodies
18. HLA-DR, DQ and DP typing using PCR amplification and immobilized probes
19. Humoral immune response against OKT3
20. Immunoprotection in spontaneous remission of type 1 diabetes: Long-term follow-up results
21. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: Observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT)
22. A comparison of childhood and adult type I diabetes mellitus
23. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: A randomized, controlled trial
24. Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type I (insulin-dependent) diabetes mellitus
25. Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity
26. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy
27. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets
28. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs
29. T helper cell subsets in insulin-dependent diabetes
30. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin
31. Cytokine gene expression in islets and thyroids of BB rats: IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats
32. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice
33. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology
34. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells
35. Signal transduction via the interleukin-4 receptor and its correlation with atopy
36. Human CD8+ T lymphocyte clones specific for T cell receptor V beta families expressed on autologous CD4+ T cells
37. Specific suppression of T helper alloreactivity by allo-MHD class I-restricted CD8+ CD28-T cells
38. Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro